28/01/2026
What the Phase 2 DFU Data Shows in Difficult-to-Heal Patients
In chronic wounds, clinical data is everything.
Especially when the study focuses on the patients who struggle to heal even with aggressive standard of care.
In this clip, Prof. Alberto Piaggesi walks through what Aurealis’ Phase 2 DFU experience suggests in harder-to-heal ulcers, and why wound chronicity matters when you’re interpreting closure endpoints.
A few data points from the Aurealis materials that investors and clinicians tend to focus on:
Phase 2 DIAMEND was a randomized controlled trial across 10 sites in Italy, Poland, and Germany. Two-week run-in period, 12-week treatment phase, follow-up through week 20.
In wounds older than 3 months, complete closure at week 20 reached 69% with AUP-16 dosed twice weekly versus 37% with standard of care alone.
In that same post-hoc subset, remaining wound area at week 20 was 6.7% versus 38.7% in the per-protocol population. That’s roughly a 5.9x reduction in residual wound size.
This is hugly impactful to the world of wound care and sets the bar high as we move into a registrational trial.
